

# Novavax to Participate in Upcoming March Investor Conferences

February 27, 2025

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences:

**TD Cowen 45<sup>th</sup> Annual Health Care Conference:**

*Fireside Chat*

Date: Tuesday, March 4, 2025  
Time: 9:10 – 9:40 a.m. Eastern Time (ET)  
Location: Boston, MA

*Conference*

Event: Investor Meetings  
Date: Tuesday, March 4, 2025

**Leerink Partners 2025 Global Healthcare Conference:**

*Presentation*

Date: Tuesday, March 11, 2025  
Time: 3:40 – 4:10 p.m. ET  
Location: Miami Beach, FL

*Conference*

Event: Investor Meetings  
Date: Tuesday, March 11, 2025

**Jefferies Biotech on the Beach Summit:**

*Conference*

Event: Investor Meetings  
Date: Wednesday, March 12, 2025  
Location: Miami Beach, FL

A webcast of the fireside chat and presentation will be available through the Events and Presentations page of the Company's website at [ir.novavax.com](https://ir.novavax.com), with replays available for 30 days after the conferences.

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including a protein-based nanoparticle and Matrix-M™ adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit [novavax.com](https://novavax.com) and [LinkedIn](#) for more information.

## Contacts:

### Investors

Luis Sanay, CFA  
240-268-2022  
[ir@novavax.com](mailto:ir@novavax.com)

### Media

Giovanna Chandler  
202-709-5563  
[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.